Company profile
OMID Holdings, Inc.
OTC: OMID · Healthcare · Drug Manufacturers - Specialty & Generic
#956 of 1,422 Healthcare companies by revenuetop-quartile growth
EA Score
48DFH 49DQ —GM 49SS 38
v0.1 · 45/100 weight · provisional
↑ Piotroski F, revenue growth (YoY) · ↓ return on equity, 3-yr revenue growth
Methodology →Revenue TTM
$394.1k
Rev growth YoY (TTM)
+59.2%
Net income (FY)
-$177.9k
Employees
6
as of 2026-08-24
Market cap
$2.1M
as of 2026-08-24
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$394.1k$394.1k2025
Net income-$177.9k-$177.9k2025
Operating income-$316.1k-$316.1k2025
Total assets$418.3k$418.3k2025
Liabilities$338.3k$338.3k2025
Equity$80.0k$80.0k2025
Revenue trend
FY2018 – FY2025 · USD
FY18
FY19
FY20
FY21
FY22
FY23
FY24
FY25
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is OMID Holdings, Inc.’s revenue?
OMID Holdings, Inc. booked $394.1k in FY2025 revenue, growing 59% year over year — faster than most Healthcare companies we track, at a -45.1% net margin.
Peers · Healthcare
iBio, Inc.48DNeurogenesis, Inc.——Lyra Therapeutics, Inc.30DAmerica Great Health39DBioRestorative Therapies, Inc.38DHealth Sciences Group, Inc.——Neighbors
Warren →Key facts
CEOAdam Frank
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
HeadquartersPhillipsburg, NJ
ExchangeOTC: OMID
Employees6
IPO date2013-03-21
Latest filings
No filings loaded — no CIK (non-SEC filer).
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.